Evidence map›Paper›PMID 42552362›Full record

ArticleBritish journal of cancer2026

AKR1B10 as a serum marker for diagnosis and postoperative monitoring of hepatocellular carcinoma.

Ming Xie, Xu Ye, Qi Yu, Wentao Tang, Yuting Ou, Miaozhi Gao, Baoluhe Zhang, Bin Wu, Zhe Cao, Xi Zeng and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ming Xie *Hunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.ORCID http://orcid.org/0000-0001-9335-0381
Xu Ye *The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, 410031, China.
Qi Yu *Hunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Wentao TangHunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Yuting OuHunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Miaozhi GaoHunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Baoluhe ZhangDepartment of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shuai-fu-yuan 1, Dongcheng District, Beijing, China.
Bin WuHunan Light of Life Biotechnology Co., Ltd, Changsha, China.
Zhe CaoHunan Light of Life Biotechnology Co., Ltd, Changsha, China.
Xi ZengHunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. xzeng@usc.edu.cn.
Shunda DuDepartment of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shuai-fu-yuan 1, Dongcheng District, Beijing, China. dushd@pumch.cn.ORCID http://orcid.org/0000-0002-9357-3259
Deliang CaoHunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. dcao@usc.edu.cn.ORCID http://orcid.org/0000-0002-5615-539X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAldo-keto reductase 1B10 (AKR1B10) is a novel serum marker for hepatocellular carcinoma (HCC). This study was aimed to evaluate its clinical value in the diagnosis and immediate postoperative monitoring for HCC.

methodsA total of 1197 subjects were recruited from two study centers, including 185 patients with HCC who underwent radical resection and followed up for 3 months. Serum samples were collected from all participants for AKR1B10 and alpha-fetoprotein (AFP) tests, and imaging and clinical data were collected.

resultsSerum AKR1B10 in HCC patients markedly increased to 1384.31 ± 107.91 pg/ml. Receiver operating characteristic (ROC) curve analysis showed an area under curve (AUC) of 0.877, sensitivity of 71.2%, and specificity of 97.2% for AKR1B10 in HCC compared to 0.792, 62.7%, and 88.7% for AFP. For early HCC, serum AKR1B10 had an AUC of 0.855, sensitivity of 70.6%, and specificity of 94.4% compared to 0.744, 56.7%, and 86.7% for AFP. After radical resection of HCC, serum AKR1B10 rapidly decreased to the normal range within 3-5 days whereas AFP remained high. At 1-3 months after surgery, serum AKR1B10 was consistent with imaging data in 89.11% of patients with HCC, whereas AFP had only 70.41%.

conclusionAKR1B10 is an effective serum marker for diagnosis of HCC and postoperative monitoring of HCC, with better clinical performance than AFP.

Identifiers

PMID42552362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.